Modular imaging device scores well

Article

The recently launched EyeScan modular ocular imaging device provides high-quality images and has the potential to save practices time and money, according to one proponent.

Dallas-The recently launched EyeScan modular ocular imaging device (Ophthalmic Imaging Systems [OIS]) provides high-quality images and has the potential to save practices time and money, said Todd Agnew, OD, a private practitioner in Dallas who was involved in beta-testing the unit.

The portable device captures both anterior and posterior segment views through six interchangeable imaging modules and can transition from capturing one type of image to another without moving the patient or the device. The device received 510(k) market clearance from the Food and Drug Administration in December.

Selling points

"What I found is that relative to the other cameras that require a decent skill set in order to capture a clear image, [the device] is much easier to go ahead and use, and even people who aren't really experienced taking pictures of the back or front surface of the eye have gotten clear pictures for me," he said. "Without a doubt, the majority of the images have been clear and easy to take."

"It's a valuable time-saver if you don't have to spend lots of time training somebody to help take those images," he said.

He also noted that the device can obtain 5.3-megapixel images, which provide better detail than images produced by some other imaging equipment, as well as capture live video segments. The maximum image capture rate is three images per second.

Recent Videos
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.